Diversity and Recruitment of Minorities in Clinical Trials: An Unmet Need
DOI:
https://doi.org/10.17140/CTPOJ-3-112Keywords:
Clinical trials, Patient recruitment, Diversity, MinoritiesAbstract
Patient centricity has led to the idea that drugs should answer medical needs not only defined by the medical bodies but relevant
for the patients themselves. This implies that the diversity of the patients should be represented in clinical trials. Disparities in
representation of diverse populations in clinical trials have been well-documented for several pathologies like arterial hypertension,
diabetes but also in oncology. Today, Caucasian patients included in clinical trials represent at least 75% of the clinical
trials population even in pathologies where minorities are largely more affected than Caucasians. Filling the gap in diversity is an
important matter to ensure ethics, good practices, regulatory compliance, patient safety and scientific validity. To achieve their
recruitment goals and being patient centric, sponsors and investigational sites need to pay attention of this problem and put in
place specific strategies. Mistrust of patients of minority groups toward clinical research is one of the main barriers along with
lack of access to clinical trials (low awareness, communication barriers, distance to investigational sites). Adapted communication,
community-based strategies are some of the useful strategies directed to the patients. Investigators may not encounter
diverse populations in their area or may not be aware of unconscious bias when identifying patients suitable for a clinical trial.
Looking for referrals and raising awareness of the risk of bias with training on culturally sounded approaches could help investigators
to recruit more diverse populations. Lack of awareness and costs may prevent sponsors to focus on diversity but ethics,
benefits of data acquisition and patient centricity should be enough motivators to modify this trend. Patients, investigators and
sponsors have their own barriers to tackle the lack of diversity in clinical trials. The cultural background of all stakeholders is
an important factor in those barriers. Only multidisciplinary approaches including human sciences would help to define patient
recruitment strategies that would mitigate the current lack of diversity.
References
Roundtable Discussion. The Ins and Outs of Incorporating Patient Centricity in Drug Development. Pharmaceutical Ex-ecutive Magazine. parexel Website. https://www.parexel.com/ news-events-resources/blog/ins-and-outs-incorporating-pa-tient-centricity-drug-development. Accessed November 15, 2019.
Barron D. Bridging the Diversity Gap in Clinical Trials. Web site. https://social.eyeforpharma.com/clinical/bridging-diversi-ty-gap-clinical-trials. Accessed January 24, 2020.
Yeoman G, Furlong P, Seres M, Binder H, Chung H, Garzya V, et al. Defining patient centricity with patients for patients and car-egivers: a collaborative endeavour. BMJ Innovations. 2017; 3(2):bm-jinnov-2016-000157. doi: 10.1136/bmjinnov-2016-000157
Merriam Webster Dictionnary. merriam Web site. https://www. merriam-webster.com/. Accessed April 23, 2020.
Limkakeng A, Phadtare A, Shah J, Vaghasia M, Wei DY, Shah A, et al. Willingness to participate in clinical trials among patients of Chinese heritage: A meta-synthesis. PLoS ONE. 2013; 8(1): e51328. doi: 10.1371/journal.pone.0051328
Hughson J, Woodward-Kron R, Parker A, Hajek J, Bresin A, Knoch U, et al. A review of approaches to improve participation of culturally and linguistically diverse populations in clinical trials. Trials. 2016; 17:263. doi: 10.1186/s13063-016-1384-3
Yancey AK, Ortega AN, Kumanyika SK. Effective re-cruitment and retention of minority research participants. Annu Rev Public Health. 2006; 27: 1-28. doi: 10.1146/annurev. publhealth.27.021405.102113
Huang B, De Vore D, Chirinos C, Wolf J, Low D, Willard-Grace R, et al. Strategies for recruitment and retention of underrepre-sented populations with chronic obstructive pulmonary disease for a clinical trial. BMC Med Res Methodol. 2019; 19(1): 39. doi: 10.1186/ s12874-019-0679-y
Nasha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of ra-cial minorities in clinical trials: Old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019; 39: 3-10. doi: 10.1200/EDBK_100021
Fisher JA, Kalbaugh CA. Challenging assumptions about mi-nority participation in US clinical research. Am J Public Health. 2011; 101(12): 2217-2222. doi: 10.2105/AJPH.2011.300279
Food and Drug Administration, Society for Women’s Health Research. Dialogues on Diversifying Clinical Trials. FDA Web site. https://www.fda.gov/media/84982/download. Accessed April 23, 2020.
Quay TA, Frimer L, Janssen PA, Lamers Y. Barriers and fa-cilitators to recruitment of South Asians to health research: A scoping review. BMJ Open. 2017; 7: e014889. doi: 10.1136/bmjop-en-2016-014889
Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Prac-tices, and Trial Designs Guidance for Industry. FDA Web site. https://www.fda.gov/regulatory-information/search-fda-guid-ance-documents/enhancing-diversity-clinical-trial-populations-el-igibility-criteria-enrollment-practices-and-trial. Accessed June 4 2019.
Liu KA, Di Pietro Mager NA. Women’s involvement in clini-cal trials: historical perspective and future implications. Pharm Pract (Granada). 2016; 14(1): 708. doi: 10.18549/PharmPract.2016.01.708
Berlin JA, Ellenberg SS. Inclusion of women in clinical trials. BMC Med. 2009; 7: 56. doi: 10.1186/1741-7015-7-56 Review | Volume 3 | Number 1 | Vives N
Ruiz Cantero MT, Pardo MA. European Medicines Agency pol-icies for clinical trials leave women unprotected. J Epidemiol Commu-nity Health. 2006; 60: 911-913. doi: 10.1136/jech.2006.048769
Labots G, Jones A, de Visser SJ, Rissman R, Burggraaf J. Gen-der differences in clinical registration trials: Is there a real problem? Br J Clin Pharmacol. 2018; 84; 700-707. doi: 10.1111/bcp.13497
Rosenberg R, Barker KA, Anderson WF. Future distribu-tion of multiple myeloma in the United States by sex, age, and race/ethnicity. Blood. 2015; 125(2): 410-412. doi: 10.1182/ blood-2014-10-609461
Food and Drug Administration. FDA Drug Trails Snapshots. fda Web site. https://www.fda.gov/drugs/drug-approvals-and-da-tabases/drug-trials-snapshots. Accessed May 18, 2020.
Oh SS, Galanter J, Thakur N, Pino-Yanes M, Barcelo NE, White MJ, et al. Diversity in clinical and biomedical research: A promise yet to be fulfilled. PLoS Med. 2015; 12(12): e1001918. doi: 10.1371/journal.pmed.1001918
Knepper T, McLeod H. When will clinical trials finally reflect diversity? Nature. 2018; 557(7704): 157-159. doi: 10.1038/d41586- 018-05049-5
World Medical Association (WMA). Declaration of Helsinki – Ethical principles for medical research involving human subjects. WMA Web site. https://www.wma.net/policies-post/wma-decla-ration-of-helsinki-ethical-principles-for-medical-research-involv-ing-human-subjects/. Accessed April 23, 2020.
International Council for Harmonisation of Technical Re-quirements for Pharmaceuticals for Human Use (ICH). ICH Topic E9 Statistical Principles for Clinical Trials. ICH Web site. https:// database.ich.org/sites/default/files/E9_Guideline.pdf. 1998. Ac-cessed April 23, 2020.
Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman KB, Caswell JL, et al. Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. Nat Com-mun. 2014; 5: 5260. doi: 10.1038/ncomms6260
Ranjit N, Siefert K, Padmanabhan V. Bisphenol-A and dispari-ties in birth outcomes: a review and directions for future research. J Perinatol. 2010; 30: 2-9. doi: 10.1038/jp.2009.90
Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, et al. Medical genetics: A marker for Stevens-Johnson syn-drome. Nature. 2004; 428: 486. doi: 10.1038/428486a
Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anas-tos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012; 206: 1453-1461. doi: 10.1093/infdis/jis508
Genovese G, Friedman DJ, Ross MD, Lecordier L. Associa-tion of trypanolytic ApoL1 variants with kidney disease in Afri-can Americans. Science. 2010; 329(5993): 841-845. doi: 10.1126/ science.1193032
Lackland DT. Racial differences in hypertension: Implications for high blood pressure management. Am J Med Sci. 2014; 348(2): 135-138. doi: 10.1097/MAJ.0000000000000308
Gupta AK. Racial Differences in Hypertension: Implications for High Blood Pressure Management. Int J Prev Med. 2010; 1(4): 217-219.
Youngmee K, Pavlish C, Evangelista LS, Kopple JD, Phillips LR. Racial/ethnic differences in illness perceptions in minority pa-tients undergoing maintenance hemodialysis. Nephrol Nurs J. 2012; 39(1): 39-49.
Otado J, Kwagyan J, Edwards D, Ukaegbu A, Rockcliffe F, Osa-fo N. Culturally competent strategies for recruitment and retention Submit your article to this journal | https://openventio.org/submit-manuscript/ Vives N of African American populations into clinical trials. Clin Transl Sci. 2015; 8(5): 460-466. doi: 10.1111/cts.12285
Sharde CT. It’s Not You, It’s Me: Necessity of Including Cul-tural Factors in Clinical Research. Law &Ineq: A Journal of Theory and Practice. 2012; 30(1): 179-209.
Galen G, Dohan D. Diversity of participants in clinical trials in an academic medical center: the role of the ‘Good Study Patient’?. Cancer. 2009; 115(3): 608-615. doi: 10.1002/cncr.24028
Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sulli-van F, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018; 2(2): MR000013. doi: 10.1002/14651858.MR000013.pub6
Epstein S. The rise of `recruitmentology’: Clinical research, racial knowledge, and the politics of inclusion and difference. Soc Stud Sci. 2008; 38(5): 801-832. doi: 10.1177/0306312708091930
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Clinical Trials and Practice – Open Journal (CTP) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.